JOTROL PK, Safety, and Food Effect Assessment

Pharmacokinetics Clinical Trial

Official title:

A Phase 1 Study to Assess the Pharmacokinetics and Safety of Ascending Doses of JOTROL Oral Gelcaps in Healthy Subjects, and to Determine the Influence of Food

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04668274
• Other study ID #: Protocol 202016
• Secondary ID: R44AG067907-01A1
• Status: Completed
• Phase: Phase 1
• Start date: January 21, 2021
• Est. completion date: May 31, 2021

Study information

• Verified date: June 2022
• Source: Jupiter Orphan Therapeutics Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Type of Study: Single Ascending Doses (SAD) Study

Objectives:

To characterize the pharmacokinetic (PK) profile of JOTROL (resveratrol) following oral administration of SAD ranging from 200 mg up to a dose currently estimated at 1,000 mg, in healthy subjects.

To evaluate the safety and tolerability of JOTROL To evaluate the effect of food on the PK profile of JOTROL. Study Design: Phase I, randomized, open-label, sequential SAD study with a food effect evaluation. Blood plasma and urine samples will be assessed for resveratrol and key metabolite content.

Type of Control: No control Test Product: JOTROL (resveratrol) 100 mg resveratrol in 1000 mg softgel capsule for oral administration Dosage Regimen: Planned dose levels of resveratrol: 200 mg, 500 mg, and 1,000 mg. Following completion of each dose level, PK, safety, and tolerability data will be evaluated; dose levels may be adjusted.

Route of Administration: Oral gelcaps with water Number of Subjects: 24 subjects will be included in Part 1; only 16 subjects, who completed Part 1, will be included in Part 2.

Subjects: Healthy, non-smoker, adult males or females, ≥ 18 and ≤ 75 years of age Study Duration: Participation of each subject in this study should last approximately 1 to 1.5 months (for subjects participating in study Part 1 only) and 1.5 to 2 months (for subjects participating in both study parts).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: May 31, 2021
• Est. primary completion date: February 28, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Normal healthy male or female volunteers, non-smokers (no use of tobacco products within 3 months prior to screening), = 18 and = 75 years of age, with BMI > 18.5 and < 30.0 kg/m 2 and body weight = 50.0 kg for males and = 45.0 kg for females

2. Healthy as defined by:

1. the absence of clinically significant illness and surgery within 4 weeks prior to dosing. Subjects vomiting within 24 hours predose will be carefully evaluated for upcoming illness/disease. Inclusion pre-dosing is at the discretion of the Investigator.

2. the absence of clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease as determined by the Investigator.

3. Females of childbearing potential who are sexually active with a male partner must be willing to use one of the following acceptable contraceptive methods throughout the study and for 30 days after the last study drug administration:

1. intra-uterine contraceptive device without hormone release system placed at least 4 weeks prior to study drug administration;

2. male condom with intravaginally applied spermicide starting at least 21 days prior to study drug administration;

3. sterile male partner (vasectomized since at least 6 months).

4. Capable of consent

Exclusion Criteria:

1. Any clinically significant abnormality at physical examination, clinically significant abnormal laboratory test results or positive test for hepatitis B, hepatitis C, or HIV found during medical screening.

2. Positive urine drug screen or urine cotinine test at screening.

3. History of allergic reactions to resveratrol, polyphenols, other related drugs, .

or to any excipient in the formulation

4. Positive pregnancy test at screening.

5. Breast-feeding subject.

6. Clinically significant ECG abnormalities or vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.

7. History of significant alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to the screening visit (more than 14 units of alcohol per week [1 unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]).

8. History of significant drug abuse within 1 year prior to screening or use of soft drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and amphetamine derivatives) within 1 year prior to screening.

9. Use of resveratrol for a medical condition or in the context of another clinical trial within a period of 30 days prior to the first dosing.

10. Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days prior to the first dosing, administration of a biological product in the context of a clinical research study within 90 days prior to the first dosing, or concomitant participation in an investigational study involving no drug or device administration.

Use of medications for the timeframes specified below, with the exception of medications exempted by the Investigator on a case-by-case basis because they are judged unlikely to affect the PK profile of the study drug or subject safety (e.g., topical drug products without significant systemic absorption):

1. prescription medication within 14 days prior to the first dosing;

2. over-the-counter products and natural health products (including herbal remedies, homeopathic and traditional medicines, probiotics, food supplements such as vitamins, minerals, amino acids, essential fatty acids, and protein supplements used in sports) within 14 days prior to the first dosing, with the exception of the occasional use of acetaminophen (up to 2 g daily);

3. use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to the first study drug administration, including St John's wort;

4. depot injection or an implant of any drug within 3 months prior to the first dosing.

12. Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at screening) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to the first dosing.

13. Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.

Related Conditions & MeSH terms

• Food-drug Interaction
• Pharmacokinetics
• Safety

Intervention

Drug:
• 200 mg resveratrol as JOTROL
Low (first) dose of single ascending dose study
• 500 mg resveratrol as JOTROL
Second (intermediate) dose of single ascending dose study
• 700 mg resveratrol as JOTROL
Third (highest) dose of single ascending dose study
• 500 mg resveratrol as JOTROL administered to assess influence of food
500 mg resveratrol as JOTROL administered to assess influence of food

Locations

Country	Name	City	State
United States	inVentiv Health Clinical Research Services LLC, a Syneos Health company (" Syneos Health ")	Miami	Florida

Sponsors (2)

Lead Sponsor	Collaborator
Jupiter Orphan Therapeutics Inc.	National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Treatment-emergent Adverse Events (TEAEs)	An adverse event (AE) was defined as any untoward medical occurrence (including clinically significant [CS] vital signs measurements or laboratory results) or worsening of a pre-existing condition in a participant administered a pharmaceutical product during the course of the study, whether related or not to the study medication. TEAEs were defined as AE that occurred on or after the date and time of study drug administration or those that first occurred pre-dose but worsened by increase in occurrence or severity after study drug administration. TEAEs includes both serious and non-serious TEAEs.	From first dose of study drug administration up to 131 days
Primary	Area Under the Plasma Concentration-time Curve From Time 0 to Time of Infinity (AUC0-inf) for Resveratrol and Its Metabolites (Resveratrol-3-glucuronide, Resveratrol-4'-Glucuronide, and Resveratrol-3-sulfate)	AUC(0-infinity) of resveratrol, resveratrol-3-glucuronide, resveratrol-4'-glucuronide, and resveratrol-3-sulfate in plasma were reported. AUC(0-infinity) of resveratrol, resveratrol-3-glucuronide, resveratrol-4'-glucuronide, and resveratrol-3-sulfate in plasma were reported and calculated as AUC0-t + Ct/Kel, where Ct is the last observed measurable concentration, AUC0-t is Area Under the Concentration-time Curve From Time Zero to the Last Measurable Concentration and Kel is Elimination rate constant.	Pre-dose and 0.133, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, and 32 hours post-dose on Day 1
Primary	Area Under the Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) for Resveratrol and Its Metabolites (Resveratrol-3-glucuronide, Resveratrol-4'-Glucuronide, and Resveratrol-3-sulfate)	AUC0-t was Area Under the Concentration-time Curve From Time Zero to the Last Measurable Concentration. AUC(0-t) was calculated according to the mixed log-linear trapezoidal rule.	Pre-dose and 0.133, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, and 32 hours post-dose on Day 1
Primary	Maximum Observed Plasma Concentration (Cmax) for Resveratrol and Its Metabolites (Resveratrol-3-glucuronide, Resveratrol-4'-Glucuronide, and Resveratrol-3-sulfate)	Cmax was the maximum observed plasma concentration obtained directly from the concentration versus time curve.	Pre-dose and 0.133, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, and 32 hours post-dose on Day 1
Secondary	Residual Area for Resveratrol	Residual area for resveratrol in plasma was calculated and reported. The residual area was calculated as 100*(1- AUC0-t / AUC0-inf) where AUC0-t (h*ng/mL) = area under the concentration-time curve from time zero to the last measurable concentration and AUC0-inf (h*ng/mL) = area under the plasma concentration-time curve from time 0 to time of infinity.	Pre-dose and 0.133, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, and 32 hours post-dose on Day 1
Secondary	Time to Maximum Observed Plasma Concentration (Tmax) for Resveratrol	Tmax was time to reach maximum observed plasma concentration obtained directly from the concentration versus time curve.	Pre-dose and 0.133, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, and 32 hours post-dose on Day 1
Secondary	Elimination Half-Life (T1/2 el) for Resveratrol	Elimination half-life was defined as the time required for the plasma concentration of drug to decrease 50 percent in the final stage of its elimination.	Pre-dose and 0.133, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, and 32 hours post-dose on Day 1
Secondary	Elimination Rate Constant (Kel) for Resveratrol	Kel was determined from the terminal slope of the log-transformed plasma concentration curve using linear regression method.	Pre-dose and 0.133, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, and 32 hours post-dose on Day 1
Secondary	Cumulative Urinary Excretion From Time Zero to Time t (Ae0-t) for Resveratrol	Cumulative urinary excretion from time zero to time t, calculated as the sum of the amounts excreted over each collection interval. The amount excreted in urine for each time interval was calculated as the urine concentration multiplied by the urine volume.	Pre-dose and 4, 8, 12, 24, and 32 hours post-dose on Day 1
Secondary	Maximum Rate of Urinary Excretion (Rmax) for Resveratrol	Maximum rate of urinary excretion, calculated by dividing the amount of drug excreted in each collection interval by the time over which it was collected.	Pre-dose and 4, 8, 12, 24, and 32 hours post-dose on Day 1
Secondary	Time of Rmax (Tmax) for Resveratrol	Tmax was the time after administration of a drug when the Rmax is reached.	Pre-dose and 4, 8, 12, 24, and 32 hours post-dose on Day 1
Secondary	Renal Clearance (CLr) for Resveratrol	CLr was calculated as Ae0-t/AUC0-t (plasma) where t is Tlast.	Pre-dose and 4, 8, 12, 24, and 32 hours post-dose on Day 1